Présentation de l'entreprise
Evolent Health, Inc. operates as a specialized provider within the healthcare sector, specifically focusing on the health information services industry, where it delivers essential administrative and management solutions for health plans. Through its subsidiary, the company executes specialty care management services across critical medical domains including oncology, cardiology, and the musculoskeletal markets throughout the United States. The enterprise is currently valued with a market capitalization of $285.79M and generates an annual revenue stream of $1.88B, supporting a workforce of 4200 employees. These financial dimensions indicate that while the company maintains a substantial operational footprint in the health information services landscape, its market valuation reflects a specific positioning that diverges from large-cap peers, suggesting a niche or cyclical exposure within the broader healthcare infrastructure.
Santé financière
The company reported a revenue of $1.88B for the trailing twelve months, yet recorded a net income of $-579,401,024, creating a significant disparity that reveals a highly leveraged cost structure where operating expenses and interest obligations substantially erode pre-tax profitability. Despite the negative net income, the organization maintains an EBITDA of $88.22M and generates free cash flow of $98.41M, which provides a degree of financial flexibility to service debt obligations or fund operational continuity despite accounting losses. The gross margin stands at 21.3%, indicating that the company retains a modest portion of revenue after direct service costs, while the operating margin of -2.1% and profit margin of -28.5% highlight substantial overhead burdens and fixed costs that impact the bottom line. On the balance sheet, the company holds $151.86M in cash against total debt of $989.70M, resulting in a debt-to-equity ratio of 238.37, which characterizes a highly leveraged position where interest coverage relies heavily on operational cash generation rather than earnings. Liquidity is managed with a current ratio of 1.31, suggesting that current assets are sufficient to cover short-term liabilities, though the margin is tight given the high debt load. Return on Equity is calculated at -66.5% and Return on Assets at -0.1%, metrics that collectively indicate that management has not yet been effective at generating positive shareholder value or asset returns, likely due to the recent restructuring costs or strategic shifts inherent in the business model.
Évaluation de la valorisation
The valuation metrics present a complex picture, with a P/E Ratio (TTM) listed as N/A due to the lack of positive earnings, while the Forward P/E is 5.80, implying that the market anticipates a significant turnaround or normalization of earnings in the future to justify any price-to-earnings multiple. The Price to Book ratio is 0.69, indicating that the market values the company at less than its book value, which often suggests that investors perceive the asset base as undervalued or that future earnings potential is currently discounted. Alternative valuation measures such as a Price to Sales ratio of 0.15 and an EV/EBITDA of 12.74 suggest that the stock is priced at a discount relative to its revenue generation and enterprise value adjusted for earnings before interest, taxes, depreciation, and amortization. The stock price has experienced significant volatility, trading between a 52-Week High of $12.06 and a 52-Week Low of $2.10, placing the current trading context within a range that reflects high uncertainty regarding future profitability. The Beta of 0.37 indicates that the stock exhibits low volatility relative to the broader market, meaning that price movements are dampened compared to the general index, offering a different risk profile for portfolios seeking lower correlation assets.
Growth & Income
The revenue growth (YoY) is recorded at -27.5%, while Earnings Growth (YoY) is N/A, reflecting a scenario where the company is currently contracting rather than expanding its top line, which precludes a traditional comparison of earnings growth speed relative to revenue. As a non-dividend payer with a Dividend Yield of N/A and a Payout Ratio of 0.0%, the company does not distribute income to shareholders, instead retaining all generated cash flows to potentially reduce its substantial debt load or invest in operational efficiencies. This reinvestment strategy is typical for firms in turnaround phases or those with high leverage, where capital allocation prioritizes solvency and balance sheet strengthening over immediate income distribution to investors. The overall growth and income profile is currently defined by contraction in revenue, a lack of dividend yield, and a reliance on cash flow generation to support a highly leveraged capital structure.